Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:908–918

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017

Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35:785–792

Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168

Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P et al (2017) Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807–3814

Xing P, Zhang F, Wang G, Xu Y, Li C, Wang S et al (2019) Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer 7:341

Berner F, Bomze D, Diem S, Ali OH, Fassler M, Ring S et al (2019) Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol 5:1043–1047

Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA et al (2015) Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 151:1206–1212

Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45–51

Reddy HG, Schneider BJ, Tai AW (2018) Immune checkpoint inhibitor-associated colitis and hepatitis. Clin Transl Gastroenterol 9:180

McGuire HM, Shklovskaya E, Edwards J, Trevillian PR, McCaughan GW, Bertolino P et al (2018) Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother 67:563–573

Spankuch I, Gassenmaier M, Tampouri I, Noor S, Forschner A, Garbe C et al (2017) Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. Eur J Cancer 81:203–205

Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA et al (2017) Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 5:417–424

Whitfield JB (2001) Gamma glutamyl transferase. Crit Rev Clin Lab Sci 38:263–355

Corti A, Franzini M, Paolicchi A, Pompella A (2010) Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting. Anticancer Res 30:1169–1181

Wu XZ, Ma F, Wang XL (2010) Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol 16:4084–4088

He WZ, Guo GF, Yin CX, Jiang C, Wang F, Qiu HJ et al (2013) Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Dis 15:e443-452

Takemura K, Fukushima H, Ito M, Kataoka M, Nakanishi Y, Sakamoto K et al (2019) Prognostic significance of serum gamma-glutamyltransferase in patients with advanced urothelial carcinoma. Urol Oncol 37:108–115

Seebacher V, Polterauer S, Grimm C, Rahhal J, Hofstetter G, Bauer EM et al (2012) Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial. Br J Cancer 106:1551–1555

Hofbauer SL, Stangl KI, de Martino M, Lucca I, Haitel A, Shariat SF et al (2014) Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma. Br J Cancer 111:1526–1531

Eskelin S, Pyrhonen S, Summanen P, Prause JU, Kivela T (1999) Screening for metastatic malignant melanoma of the uvea revisited. Cancer 85:1151–1159

Kaiserman I, Amer R, Pe’er J (2004) Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 137:236–243

Hendler K, Pe’er J, Kaiserman I, Baruch R, Kalickman I, Barak V et al (2011) Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2). Anticancer Res 31:351–357

Mouriaux F, Diorio C, Bergeron D, Berchi C, Rousseau A (2012) Liver function testing is not helpful for early diagnosis of metastatic uveal melanoma. Ophthalmology 119:1590–1595

Giobbie-Hurder A, Gelber RD, Regan MM (2013) Challenges of guarantee-time bias. J Clin Oncol 31:2963–2969

Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A et al (2013) Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31:1071–1077

Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS et al (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3:1185–1192

Doherty GJ, Duckworth AM, Davies SE, Mells GF, Brais R, Harden SV et al (2017) Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open 2:e000268

Imoto K, Kohjima M, Hioki T, Kurashige T, Kurokawa M, Tashiro S et al (2019) Clinical features of liver injury induced by immune checkpoint inhibitors in japanese patients. Can J Gastroenterol Hepatol 2019:6391712

Mizuno K, Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T et al (2020) Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol 55:653–661

Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H et al (2020) Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol 26:353–365

Tan B, Li Y, Xu Y, Chen M, Wang M, Qian J (2020) Recognition and management of the gastrointestinal and hepatic immune-related adverse events. Asia Pac J Clin Oncol 16:95–102

Pompella A, De Tata V, Paolicchi A, Zunino F (2006) Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol 71:231–238

Hann HW, Wan S, Myers RE, Hann RS, Xing J, Chen B et al (2012) Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS ONE 7:e47687

Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY et al (2013) Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS ONE 8:e61448

Zhu J, Jiang F, Ni HB, Xiao MB, Chen BY, Ni WK et al (2013) Combined analysis of serum gamma-glutamyl transferase isoenzyme II, alpha-L-fucosidase and alpha-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma. Exp Ther Med 5:89–94

Xu XS, Wan Y, Song SD, Chen W, Miao RC, Zhou YY et al (2014) Model based on gamma-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis. World J Gastroenterol 20:10944–10952

Wu SJ, Lin YX, Ye H, Xiong XZ, Li FY, Cheng NS (2016) Prognostic value of alkaline phosphatase, gamma-glutamyl transpeptidase and lactate dehydrogenase in hepatocellular carcinoma patients treated with liver resection. Int J Surg 36:143–151

Huang R, Yang CC, Liu Y, Xia J, Su R, Xiong YL et al (2015) Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients. World J Gastroenterol 21:9957–9965

Yavuz BB, Yavuz B, Halil M, Cankurtaran M, Ulger Z, Cankurtaran ES et al (2008) Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer’s disease. Int Psychogeriatr 20:815–823

Koehler EM, Sanna D, Hansen BE, van Rooij FJ, Heeringa J, Hofman A et al (2014) Serum liver enzymes are associated with all-cause mortality in an elderly population. Liver Int 34:296–304

Koenig G, Seneff S (2015) Gamma-glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease Risk. Dis Markers 2015:818570

Melezinek I, Borovansky J, Elleder M, Bubnova E (1998) Tumour tissue is a source of gamma-glutamyl transpeptidase sialoform in the sera of melanoma-bearing mice. Melanoma Res 8:39–45

Obrador E, Carretero J, Ortega A, Medina I, Rodilla V, Pellicer JA et al (2002) Gamma-glutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. Hepatology 35:74–81

Sacchetti L, Castaldo G, Cimino L, Budillon G, Salvatore F (1988) Diagnostic efficiency in discriminating liver malignancies from cirrhosis by serum gamma-glutamyltransferase isoforms. Clin Chim Acta 177:167–172

Castaldo G, Oriani G, Lofrano MM, Cimino L, Topa M, Budillon G et al (1996) Differential diagnosis between hepatocellular carcinoma and cirrhosis through a discriminant function based on results for serum analytes. Clin Chem 42:1263–1269